Iron and Its Role in Cancer Defense: A Double-Edged Sword
- PMID: 29394034
- DOI: 10.1515/9783110470734-021
Iron and Its Role in Cancer Defense: A Double-Edged Sword
Abstract
Iron (Fe) is an essential metal, vital for biological functions, including electron transport, DNA synthesis, detoxification, and erythropoiesis that all contribute to metabolism, cell growth, and proliferation. Interactions between Fe and O2 can result in the generation of reactive oxygen species (ROS), which is based on the ability of Fe to redox cycle. Excess Fe may cause oxidative damage with ensuing cell death, but DNA damage may also lead to permanent mutations. Hence Fe is carcinogenic and may initiate tumor formation and growth, and also nurture the tumor microenvironment and metastasis. However, Fe can also contribute to cancer defense. Fe may induce toxic ROS and/or initiate specific forms of cell death, including ferroptosis that will benefit cancer treatment. Furthermore, Fe-binding and Fe-regulatory proteins, such as hepcidin, lipocalin-2/NGAL, heme oxygenase-1, ferritin, and iron-sulfur clusters can display antitumor properties under specific conditions and in particular cancer types. In addition, the milk protein lactoferrin may synergize with other established anticancer agents in the prevention and therapy of cancer. Consequently, drugs that target Fe metabolism in tumors are promising candidates for the prevention and therapy of cancer, but consideration of context specificity (e.g., tumor type; systemic versus tumor microenvironment Fe homeostasis) is mandatory.
Similar articles
-
The medicinal chemistry of novel iron chelators for the treatment of cancer.Curr Top Med Chem. 2011;11(5):483-99. doi: 10.2174/156802611794785190. Curr Top Med Chem. 2011. PMID: 21192781 Review.
-
Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells.PLoS One. 2015 Sep 14;10(9):e0137800. doi: 10.1371/journal.pone.0137800. eCollection 2015. PLoS One. 2015. PMID: 26368127 Free PMC article.
-
Lipocalin-2 and iron trafficking in the tumor microenvironment.Pharmacol Res. 2017 Jun;120:146-156. doi: 10.1016/j.phrs.2017.03.018. Epub 2017 Mar 23. Pharmacol Res. 2017. PMID: 28342790 Review.
-
A promising new approach to cancer therapy: Targeting iron metabolism in cancer stem cells.Semin Cancer Biol. 2018 Dec;53:125-138. doi: 10.1016/j.semcancer.2018.07.009. Epub 2018 Jul 30. Semin Cancer Biol. 2018. PMID: 30071257 Review.
-
Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.Eur J Pharmacol. 2016 Jun 15;781:209-17. doi: 10.1016/j.ejphar.2016.04.026. Epub 2016 Apr 14. Eur J Pharmacol. 2016. PMID: 27090924
Cited by
-
Iron in the Tumor Microenvironment-Connecting the Dots.Front Oncol. 2018 Nov 26;8:549. doi: 10.3389/fonc.2018.00549. eCollection 2018. Front Oncol. 2018. PMID: 30534534 Free PMC article. Review.
-
Identification and Quantification of Iron Metabolism Landscape on Therapy and Prognosis in Bladder Cancer.Front Cell Dev Biol. 2022 Feb 21;10:810272. doi: 10.3389/fcell.2022.810272. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35265613 Free PMC article.
-
The role of iron homeostasis and iron-mediated ROS in cancer.Am J Cancer Res. 2021 May 15;11(5):1895-1912. eCollection 2021. Am J Cancer Res. 2021. PMID: 34094660 Free PMC article. Review.
-
The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia.Front Physiol. 2024 Feb 26;15:1346173. doi: 10.3389/fphys.2024.1346173. eCollection 2024. Front Physiol. 2024. PMID: 38468700 Free PMC article. Review.
-
Iron accumulation typifies renal cell carcinoma tumorigenesis but abates with pathological progression, sarcomatoid dedifferentiation, and metastasis.Front Oncol. 2022 Aug 5;12:923043. doi: 10.3389/fonc.2022.923043. eCollection 2022. Front Oncol. 2022. PMID: 35992801 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
